Skip to main content
Jonathan Cheng, MD, Oncology, Philadelphia, PA

Jonathan Cheng MD


Physician

Join to View Full Profile
  • 333 Cottman AveFox Chase Cancer CenterPhiladelphia, PA 19111

  • Phone+1 215-728-6900

  • Fax+1 215-728-3639

Dr. Cheng is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Temple University Hospital-Fox Chase Cancer Center
    Temple University Hospital-Fox Chase Cancer CenterFellowship, Hematology and Medical Oncology, 1998 - 1999
  • University at Buffalo
    University at BuffaloFellowship, Hematology and Medical Oncology, 1996 - 1998
  • University of Minnesota
    University of MinnesotaResidency, Internal Medicine, 1992 - 1995
  • University of Minnesota Medical School
    University of Minnesota Medical SchoolClass of 1992

Certifications & Licensure

  • PA State Medical License
    PA State Medical License 1998 - 2024
  • MN State Medical License
    MN State Medical License 1994 - 1997
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2014-2017
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014-2017
  • CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014-2017

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Pan-Tumor Genomic Biomarkers for PD-1 Checkpoint Blockade–Based Immunotherapy  
    Jonathan Cheng, Patrick A Ott, Elizabeth R Plimack, Antoni Ribas, Andrew Joe, Science Magazine

Press Mentions

  • Global Launch Event for Iza-Bren Phase III Nasopharyngeal Carcinoma Research Results Successfully Held, Streamed on ESMO Official Website
    Global Launch Event for Iza-Bren Phase III Nasopharyngeal Carcinoma Research Results Successfully Held, Streamed on ESMO Official WebsiteOctober 24th, 2025
  • According to New Multinational Survey, Healthcare Providers Believe Immunotherapy Has Potential to Positively Impact Earlier-Stage Cancer Treatment Landscape Across Tumor Types
    According to New Multinational Survey, Healthcare Providers Believe Immunotherapy Has Potential to Positively Impact Earlier-Stage Cancer Treatment Landscape Across Tumor TypesSeptember 13th, 2021
  • MiR Scientific Snags BMS Melanoma, Genitourinary Commercial Leader for Cancer Detection Test
    MiR Scientific Snags BMS Melanoma, Genitourinary Commercial Leader for Cancer Detection TestAugust 13th, 2021

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: